Commercial Launch Capitalize on Orasis presbyopia eye drop Qlosi launch readiness and recent Series D funding to position sales outreach around ophthalmology clinics and retail partners; target states permitting in-office dispensing to expand patient access.

Access Programs Leverage First Fill Free program and BlinkRx distribution to lower patient barriers and accelerate formulary adoption; pursue partnerships with payers and patient support programs to drive trial and ongoing usage.

Quality & Ops Engage Orasis leadership known for quality and operations expansion to discuss scalable supply, regulatory compliance, and co-promotion opportunities; offer value through robust manufacturing and quality systems alignment.

Presbyopia Focus Target ophthalmology practices, optometry networks, and vision centers emphasizing presbyopia treatment adoption; present Qlosi as a differentiated corrective eye drop to expand near-vision patient care portfolios.

Growth Horizon With $126M funding and a clear commercial launch trajectory, propose strategic collaborations for distribution, training, and analytics services (HubSpot, Zoho, Piwik PRO) to optimize field sales, customer relationships, and market intelligence.